Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2022-07-06 00:00:00 ET · period of report 2022-07-05 · accession 0001209191-22-041330 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-06 | 2022-07-06 | DYN | Brumm Joshua T | See Remarks, Dir | D - Sale to Iss | $8.24 | -11.0K | 219.9K | -5% | -$90.3K |
| D | 2022-07-06 | 2022-07-05 | DYN | Brumm Joshua T | See Remarks, Dir | A - Grant | $0.00 | +24.1K | 230.9K | +12% | $0 |
| DM | 2022-07-06 | 2022-07-05 | DYN | Brumm Joshua T | See Remarks, Dir | A - Grant | $0.00 | +232.3K | 78.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-07-06 | D | D | 10,963 | $8.24 | 219,939 | D | — | — | (F3) Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of PRSUs granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $8.24 to $8.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. (F2) Includes 183,688 unvested RSUs. |
| 2 | Common | Common Stock | 2022-07-05 | A | A | 24,118 | $0.00 | 230,902 | D | — | — | (F1) The Performance Restricted Stock Units (PRSUs) were granted on September 17, 2020, with 100% of the PRSUs to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. (F2) Includes 183,688 unvested RSUs. |
| 3 | Derivative | Stock Option (right to buy) | 2022-07-05 | A | A | 153,931 | $0.00 | 153,931 | D | $5.54 · — to 2030-07-30 | 153,931 Common Stock | (F5) The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |
| 4 | Derivative | Stock Option (right to buy) | 2022-07-05 | A | A | 78,386 | $0.00 | 78,386 | D | $19.00 · — to 2030-09-15 | 78,386 Common Stock | (F6) The option was granted on September 16, 2020, with 100% of the option to vest upon the clearance date of an IND application submitted to the FDA by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |